Bristol-Myers Squibb (United Kingdom)

Recent papers from Bristol-Myers Squibb (United Kingdom)

1. Bivariate Copula Models With Event‐Free Cure Effect for Survival Extrapolations and Individual‐Level Correlation AnalysisStatistics in Medicine · 2026
2. Treatment patterns and clinical outcomes in patients with loco-regional recurrent melanoma in the United KingdomBMC Cancer · 2026
3. Structure-Based Design of 2-(Pyridone)Indoles as Antagonists of the Toll-Like Receptors TLR7 and TLR8 for the Treatment of Autoimmune DisordersJournal of Medicinal Chemistry · 2026
4. Inequalities in oral anticoagulant treatment patterns: a two-part model to estimate healthcare costs associated with atrial fibrillationENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2026
5. Nivolumab plus relatlimab with platinum-doublet chemotherapy versus nivolumab with platinum-doublet chemotherapy in stage IV or recurrent non-small cell lung cancer: clinical, translational, and patient-reported outcomes results from the phase II RELATIVITY-104 studyAnnals of Oncology · 2026
6. Mechanistic Insights into Drug Release from PLGA- and PLA-Based ImplantsMolecular Pharmaceutics · 2026
7. Safety Profile of Chimeric Antigen Receptor T-cell Therapies in Diffuse Large B-cell Lymphoma: An Analysis of Real-World Adverse Event Reporting From the FDA Adverse Event Reporting SystemMayo Clinic Proceedings Innovations Quality & Outcomes · 2026
8. Plain language summary of the RELATIVITY-098 study results: nivolumab plus relatlimab given after melanoma is removed by surgeryFuture Oncology · 2026
9. Evolution of Real-World Treatment Patterns over Time in Patients with HER2-Negative Advanced Gastric Cancer: A Retrospective Database Cohort Study from JapanAdvances in Therapy · 2026
10. Assessment of the Value of Nivolumab Plus Ipilimumab for Treating Microsatellite Instability-High/Mismatch Repair Deficiency Metastatic Colorectal Cancer: Indirect Treatment Comparison and Cost-Effectiveness AnalysisAdvances in Therapy · 2026
11. TPST Gene Knock‐Out Eliminates Tyrosine Sulfation on a Recombinant Antibody Produced in CHO CellsBiotechnology Journal · 2026
12. Real-World Use of Adjuvant Nivolumab for Resected Stage III–IV Melanoma: 2-Year Analysis of AdjuMelDermatology and Therapy · 2026
13. Discovery of BMS-986449: A Potent, Selective Degrader of the Transcription Factors IKZF2 (Helios) and IKZF4 (Eos) to Target Regulatory T Cells in Solid TumorsJournal of Medicinal Chemistry · 2026
14. Ion Mobility-Collision Induced Unfolding Detects Stability Shifts within Hidden Protein Conformer FamiliesJournal of the American Society for Mass Spectrometry · 2026
15. StructuredHTE Data and Integrated Bayesian OptimizationAccelerate Scalable Amidation Process DevelopmentACS Organic & Inorganic Au · 2026
16. Biomarkers of nivolumab benefit in resectable non-small cell lung cancerNature · 2026
17. Diastereoselective Synthesis of a Medicinally Significant Cis −1,1,3‐Trisubstituted Cyclopentane Derivative through Epoxide Ring OpeningEuropean Journal of Organic Chemistry · 2026
18. Identificationand Studies of Highly Potent and SelectiveHeterobifunctional Galectin-3 DegradersACS Medicinal Chemistry Letters · 2026
19. The Synthetic Roleof PFAS in Drug Substance Manufacturing:An IQ Consortium Working Group Review on the Potential Impact of PFASRestrictions on Patient Access to MedicinesOrganic Process Research & Development · 2026
20. Development of the Commercial Manufacturing Process for Xanomeline Tartrate, an Active Pharmaceutical Ingredient in KarXTOrganic Process Research & Development · 2026